Literature DB >> 9870557

Biomarkers of oxidative stress are significantly elevated in Down syndrome.

S V Jovanovic1, D Clements, K MacLeod.   

Abstract

There is convincing epidemiological and in vitro evidence of chronic oxidative stress in individuals with Down syndrome (DS). These individuals develop Alzheimer like changes in the brain in their 30s and 40s. The incidence of autoimmune diseases and cataracts is significantly increased, and the overall ageing process is accelerated. In vitro studies show that impaired viability of DS neurons may be amended by simple chemical antioxidants, such as vitamin E, BHT and propyl gallate, clearly indicative of oxyl radical involvement. However, because of the lack of in vivo experiments, the role of oxidative stress in DS remains controversial. We report here on the results of the chemical analyses of urine samples of 166 individuals, where DS subjects were matched by their siblings. The levels of 8-hydroxy-2'-deoxyguanosine (2.35 +/- 1.69 in DS vs. 1.35 +/- 1.04 in controls, P = 0.00011), a biomarker of oxidative damage to DNA, and malondialdehyde (0.255 +/- 0.158 in DS vs. 0.204 +/- 0.128 in controls, P = 0.033), a biomarker of lipid peroxidation, are significantly elevated in individuals with DS. Dietary influences failed to show any significant correlation with the oxidative stress biomarkers. These results provide direct evidence for increased oxidative stress in individuals with DS.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9870557     DOI: 10.1016/s0891-5849(98)00137-3

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  39 in total

Review 1.  An overview and update regarding medical problems in Down syndrome.

Authors:  V Grech
Journal:  Indian J Pediatr       Date:  2001-09       Impact factor: 1.967

2.  Bach1 overexpression in Down syndrome correlates with the alteration of the HO-1/BVR-a system: insights for transition to Alzheimer's disease.

Authors:  Fabio Di Domenico; Gilda Pupo; Cesare Mancuso; Eugenio Barone; Francesca Paolini; Andrea Arena; Carla Blarzino; Frederick A Schmitt; Elizabeth Head; D Allan Butterfield; Marzia Perluigi
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

3.  Association between frontal cortex oxidative damage and beta-amyloid as a function of age in Down syndrome.

Authors:  Giovanna Cenini; Amy L S Dowling; Tina L Beckett; Eugenio Barone; Cesare Mancuso; Michael Paul Murphy; Harry Levine; Ira T Lott; Frederick A Schmitt; D Allan Butterfield; Elizabeth Head
Journal:  Biochim Biophys Acta       Date:  2011-10-08

4.  An investigation of the molecular mechanisms engaged before and after the development of Alzheimer disease neuropathology in Down syndrome: a proteomics approach.

Authors:  Giovanna Cenini; Ada Fiorini; Rukhsana Sultana; Marzia Perluigi; Jian Cai; Jon B Klein; Elizabeth Head; D Allan Butterfield
Journal:  Free Radic Biol Med       Date:  2014-08-20       Impact factor: 7.376

Review 5.  Redox proteomics and amyloid β-peptide: insights into Alzheimer disease.

Authors:  D Allan Butterfield; Debra Boyd-Kimball
Journal:  J Neurochem       Date:  2018-11-27       Impact factor: 5.372

6.  Superoxide dismutase 1 modulates expression of transferrin receptor.

Authors:  Ruth Danzeisen; Tilmann Achsel; Ulrich Bederke; Mauro Cozzolino; Claudia Crosio; Alberto Ferri; Malte Frenzel; Edith Butler Gralla; Lea Huber; Albert Ludolph; Monica Nencini; Giuseppe Rotilio; Joan Selverstone Valentine; Maria Teresa Carrì
Journal:  J Biol Inorg Chem       Date:  2006-04-26       Impact factor: 3.358

7.  α-Tocopherol supplementation reduces biomarkers of oxidative stress in children with Down syndrome: a randomized controlled trial.

Authors:  S Mustafa Nachvak; T Reza Neyestani; S Ali Mahboob; S Sabour; S Ali Keshawarz; J R Speakman
Journal:  Eur J Clin Nutr       Date:  2014-06-18       Impact factor: 4.016

8.  Significant modifications of the salivary proteome potentially associated with complications of Down syndrome revealed by top-down proteomics.

Authors:  Tiziana Cabras; Elisabetta Pisano; Caterina Montaldo; Maria Rita Giuca; Federica Iavarone; Giuseppe Zampino; Massimo Castagnola; Irene Messana
Journal:  Mol Cell Proteomics       Date:  2013-03-26       Impact factor: 5.911

Review 9.  Amyloid β-peptide (1-42)-induced oxidative stress in Alzheimer disease: importance in disease pathogenesis and progression.

Authors:  D Allan Butterfield; Aaron M Swomley; Rukhsana Sultana
Journal:  Antioxid Redox Signal       Date:  2013-02-14       Impact factor: 8.401

10.  Supplementation with antioxidants and folinic acid for children with Down's syndrome: randomised controlled trial.

Authors:  Jill M Ellis; Hooi Kuan Tan; Ruth E Gilbert; David P R Muller; William Henley; Robert Moy; Rachel Pumphrey; Cornelius Ani; Sarah Davies; Vanessa Edwards; Heather Green; Alison Salt; Stuart Logan
Journal:  BMJ       Date:  2008-02-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.